FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.
What happened
FDA inspected the Granules India finished-drug plant in Gagillapur Village, Telangana, from August 26 to September 6, 2024. Swabs of air ducts after the HEPA filters (high-efficiency filters that clean air going into production) showed residues of several previously made drug products plus microbial contamination too numerous to count, and bird droppings and feathers were seen on air handling units inside the facility. Investigators also found a large amount of torn CGMP records in at least 15 plastic waste bags.
What FDA found
The company did not properly clean and maintain production equipment, allowing drug residues and heavy microbial contamination to build up in air ducts after the HEPA filters.
21 CFR 211.67(b)The building was not kept in good repair: bird droppings and feathers were on air handling units, ducts, a tank and the floors.
21 CFR 211.58The company did not adequately inspect, calibrate and maintain its air handling units and HEPA filters, so damaged filters and leaks went undetected.
21 CFR 211.68(a)Torn CGMP records, including balance printouts and worksheets with manufacturing and testing data, were found in at least 15 waste bags, so the quality system does not assure data integrity.
What FDA wants
FDA asks the company to reply in writing within 15 working days describing what it has done to fix each violation and prevent recurrence. It specifically wants an independent retrospective review of cleaning effectiveness, plus CAPA (corrective and preventive action) plans for cleaning, facilities and equipment oversight.
Who should pay attention
- brands and marketers that buy finished drugs from this contract manufacturer
- companies listing this site as a manufacturer in their drug applications
- quality teams that qualify and audit overseas suppliers
This is a summary. Read the original letter on fda.gov.